Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterActive in the last 2 years

Al B. Benson

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-5485-7227; OpenAlex author ID A5029706633, A5109372881, A5112032805, A5158594644; NIH RePORTER profile ID 1894210. Sources: ClinicalTrials.gov.

Their work

Papers
29 (first author 3, last author 4)
Trials
2
Grants
1
Labs led
1
Collaborators
136
Papers, trials and grants by year

1998: 1 trial · 1999: 1 trial · 2000: none · 2001: none · 2002: none · 2003: none · 2004: none · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 5 papers · 2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: 4 papers · 2017: 2 papers · 2018: 1 paper · 2019: 2 papers · 2020: 5 papers · 2021: 3 papers · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers, 1 grant

Papers 29

  1. KRAS Subtype Modifies Outcomes with Immunomodulatory Therapy in Advanced Pancreatic Ductal Adenocarcinoma: Evidence from Early-Phase Trials. Co-author DOI 10.3390/cancers18132037↗
  2. Pancreatic Adenocarcinoma, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. Co-author DOI 10.6004/jnccn.2026.0046↗
  3. Real-World Validation of the Purity Independent Subtyping of Tumors Classifier for Informing Therapy Selection in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1200/po-25-00197↗
  4. Are We There Yet? - Alternating Chemotherapy Regimens in Pancreatic Cancer. First author DOI 10.1056/evide2300341↗
  5. Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC). Co-author DOI 10.1038/s41416-023-02344-5↗
  6. Detection of Immunotherapeutic Response in a Transgenic Mouse Model of Pancreatic Ductal Adenocarcinoma Using Multiparametric MRI Radiomics: A Preliminary Inve… Co-author DOI 10.1016/j.acra.2020.04.026↗
  7. Impact of Diabetes and Insulin Use on Prognosis in Patients With Resected Pancreatic Cancer: An Ancillary Analysis of NRG Oncology RTOG 9704. Co-author DOI 10.1016/j.ijrobp.2020.08.042↗
  8. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2021.0017↗
  9. Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. Co-author DOI 10.1136/jitc-2020-000587↗
  10. MRI radiomics for early prediction of response to vaccine therapy in a transgenic mouse model of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12967-020-02246-7↗
  11. Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study. Co-author DOI 10.1634/theoncologist.2019-0473↗
  12. Dinaciclib prolongs survival in the LSL-Kras G12D/+ ; LSL-Trp53R172H/+ ; Pdx-1-Cre (KPC) transgenic murine models of pancreatic ductal adenocarcinoma. Co-author PMID 32269732↗
  13. Prediction of therapeutic outcome and survival in a transgenic mouse model of pancreatic ductal adenocarcinoma treated with dendritic cell vaccination or CDK i… Co-author PMID 32509212↗
  14. Pancreatic Adenocarcinoma, Version 1.2019. Co-author DOI 10.6004/jnccn.2019.0014↗
  15. Magnetic resonance imaging monitoring therapeutic response to dendritic cell vaccine in murine orthotopic pancreatic cancer models. Co-author PMID 30949410↗
  16. An Extremely Rapid Case of Pneumonitis with the Use of Nivolumab for Pancreatic Adenocarcinoma. First author DOI 10.1155/2018/6314392↗
  17. A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreat… Co-author DOI 10.1634/theoncologist.2017-0024↗
  18. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2017.0131↗
  19. Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Grou… Last author DOI 10.1097/coc.0000000000000068↗
  20. Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach. Co-author DOI 10.1097/mpa.0000000000000710↗
  21. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Co-author DOI 10.1200/jco.2016.67.5561↗
  22. Is There Efficacy Beyond Cytotoxic Chemotherapy for Pancreatic Cancer? First author DOI 10.1200/jop.2016.015883↗
  23. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. Co-author DOI 10.6004/jnccn.2014.0106↗
  24. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. Co-author DOI 10.6004/jnccn.2012.0073↗
  25. Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized panc… Co-author DOI 10.1016/j.ijrobp.2010.02.030↗
  26. The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for panc… Co-author DOI 10.1016/j.ijrobp.2010.07.1993↗
  27. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. Last author DOI 10.1200/jco.2011.34.8904↗
  28. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S… Co-author DOI 10.1245/s10434-011-1630-6↗
  29. Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients. Last author DOI 10.1586/era.11.125↗

Trials 2

  1. Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors Study chair NCT00004095↗
  2. Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the Pancreas Study chair NCT00003216↗

Grants 1

  1. Northwestern University Lead Academic Participating Site UG1CA308665↗

Closest collaborators

The 25 strongest of 136 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniela E Matei · 1 shared grant, 2026 · strength 1.26
  2. Aparna Kalyan · 5 shared papers, 2016–2026 · strength 0.78
  3. Mary F. Mulcahy · 6 shared papers, 2011–2026 · strength 0.74
  4. Vahid Yaghmai · 6 shared papers, 2018–2021 · strength 0.65
  5. Sheetal Mehta Kircher · 4 shared papers, 2011–2026 · strength 0.60
  6. Jia Ying Yang · 5 shared papers, 2019–2021 · strength 0.57
  7. Zhuoli Zhang · 5 shared papers, 2019–2021 · strength 0.57
  8. Aydın Eresen · 4 shared papers, 2020–2021 · strength 0.49
  9. Andrew H. Ko · 7 shared papers, 2012–2026 · strength 0.47
  10. Vaibhav Sahai · 1 shared paper, 2024 · strength 0.46
  11. Devalingam Mahalingam · 2 shared papers, 2023–2026 · strength 0.45
  12. Brian G. Czito · 6 shared papers, 2012–2026 · strength 0.43
  13. Robert A. Wolff · 6 shared papers, 2012–2026 · strength 0.43
  14. Eric K. Nakakura · 6 shared papers, 2012–2026 · strength 0.43
  15. Mokenge Peter Malafa · 6 shared papers, 2012–2026 · strength 0.43
  16. Brian Matthew Wolpin · 6 shared papers, 2012–2026 · strength 0.43
  17. Andrew M. Lowy · 5 shared papers, 2014–2026 · strength 0.41
  18. Vincent M. Chung · 5 shared papers, 2014–2026 · strength 0.41
  19. Elena Gabriela Chiorean · 5 shared papers, 2014–2026 · strength 0.41
  20. Noelle K. LoConte · 4 shared papers, 2017–2026 · strength 0.38
  21. Courtney L. Scaife · 4 shared papers, 2017–2026 · strength 0.38
  22. Jeffrey M. Hardacre · 4 shared papers, 2017–2026 · strength 0.38
  23. Dana Backlund Cardin · 4 shared papers, 2017–2026 · strength 0.38
  24. Mary E. Dillhoff · 4 shared papers, 2017–2026 · strength 0.38
  25. Halla Sayed Nimeiri · 3 shared papers, 2011–2025 · strength 0.35

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.